CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article
Click on image to view larger version.



Fig. 4. Farnesylated, but not unprenylated, RhoA(63L) retains the ability to promote growth in low serum. NIH 3T3 cells stably expressing RhoA(63L)-WT, RhoA(63L)-CVLS, or RhoA(63L)-SLVL were plated at 103 cells/dish and allowed to adhere in DMEM supplemented with 10% calf serum. Untransformed cells stably transfected with the empty pZIP-NeoSV(x)1 plasmid (Vector) were included as a control. After 24 h, the medium was replaced with DMEM supplemented with 0.5% calf serum. Twenty-one days after plating, the cells were fixed and stained with 0.4% crystal violet (A) to better visualize the cells. On day 20, the cells were photographed (B) to demonstrate the different morphology of the cells.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation